Evaluating the use of enforced clozapine in an Australian forensic psychiatric setting: two cases

Kasinathan, John; Mastroianni, Tony
January 2007
BMC Psychiatry;2007 Supplement 1, Vol. 7, Special section p1
Academic Journal
Background To evaluate the administration, outcomes and ethical issues of enforced clozapine in two patients with treatment-resistant schizophrenia/schizoaffective disorder in a forensic psychiatric setting, who were refusing oral clozapine. Methods "Enforced clozapine" implied that if a patient refused oral clozapine they received intramuscular clozapine at half the expected oral dose. The case series involved 12 months follow-up. Baseline and monthly measures included the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions (CGI), Global Assessment of Functioning (GAF), Insight and Treatment Attitudes Questionnaire (ITAQ) and Quality of Life Self-Assessment Inventory (QLS-100). Routine haematological, metabolic and cardiac monitoring was informed by established clinical guidelines. Statistical analysis utilized t-Tests and Pearson's correlation coefficient. Results Enforced clozapine was reasonably well tolerated with rapid acceptance of oral clozapine. By 12 months, statistically significant improvements were seen in BPRS (p = 0.05), CGI (p = 0.04) and GAF (p = 0.03). Improvements in ITAQ and QLS-100 were not statistically significant. BPRS and CGI were strongly negatively correlated with the length of time on enforced clozapine, clozapine dose and clozapine serum levels. GAF, QLS-100 and to a lesser extent ITAQ were positively correlated with those factors. Conclusion Enforced clozapine is a viable short-term treatment option in treatment-resistant patients who are refusing oral clozapine. It resulted in significantly reduced psychotic symptoms, reduced dangerousness, a better quality of life, improved insight into their illness and long-term acceptance of oral clozapine. Unfortunately recent global non-production of parenteral clozapine means that this promising intervention in selected treatment-resistant patients cannot be further evaluated and judiciously implemented.


Related Articles

  • CLOZAPINE INDUCED PARALYTIC ILEUS. Nayak, Veena; Chogtu, Bharti; Devaramane, Virupaksha; Vasudeva, S.; Bhandary, P. V. // Journal of Pharmaceutical Research & Health Care;Oct2010, Vol. 2 Issue 4, p330 

    Clozapine is an atypical antipsychotic drug used for the treatment of schizophrenia in patient not responding to other antipsychotics. Dry mouth, constipation, loss of accommodation and urinary retention are the common side effects encountered with this drug. Here we are reporting a case of...

  • Acceptability and Disintegration Rates of Orally Disintegrating Risperidone Tablets in Patients With Schizophrenia or Schizoaffective Disorder. Chue, Pierre; Welch, Ron; Binder, Carin // Canadian Journal of Psychiatry;Oct2004, Vol. 49 Issue 10, p701 

    Objective: To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Method: Ten patients stable for at least 10 days on monotherapy with oral risperidone 2 mg to 4 mg taken...

  • Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Nosè, Michela; Accordini, Simone; Artioli, Paola; Barale, Francesco; Barbui, Corrado; Beneduce, Rossella; Berardi, Domenico; Bertolazzi, Gerardo; Biancosino, Bruno; Bisogno, Alfredo; Bivi, Raffaella; Bogetto, Filippo; Boso, Marianna; Bozzani, Alberto; Bucolo, Piera; Casale, Marcello; Cascone, Liliana; Ciammella, Luisa; Cicolini, Alessia; Cipresso, Gabriele // Trials;2009, Vol. 10, p1 

    Background: One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as...

  • Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia. Kumar, Vijaya; Sharma, Lavanya; Madival, Srikanth; Venkatasubramanian, Ganesan // Journal of Psychiatry & Neuroscience;Jan2016, Vol. 41 Issue 1, pE1 

    The article describes the case of a 57 year old woman with treatment-resistant schizophrenia who was started on clozapine to augment her ongoing treatment with olanzapine. The adverse effects decreased after the caregiver changed her medication regimen where she was given 15 milligram (mg) of...

  • SHAKE IT UP! Schaaf, Rachelle Vander // Parenting;Sep2000, Vol. 14 Issue 7, p35 

    Stresses the need to follow the Shake before using label of some medicines. Forms of medicines that come in liquid or suspension form; Why some medicines need to be shaken; Consequence of not shaking medicines.

  • Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Castillo, Enrico G.; Stroup, T. Scott // Medical Humanities;May2015, Vol. 18 Issue 2, p36 

    The article reports on the effectiveness of the antipsychotic long-acting injectable (LAI). Topics discussed include the risk of schizophrenia, the antipsychotic medications management, and the schizophrenia patients management. Also mentioned are the randomised controlled trials for LAI, the...

  • In vivo immunomodulatory effects of clozapine in schizophrenia. Hornig, Mady; Maes, M.; Bosmans, E.; Kenis, G.; De Jong, R.; Smith, R.S.; Meltzer, H.Y. // Advances in Mind-Body Medicine;Winter2000, Vol. 16 Issue 1, p52 

    Presents an abstract of the article 'In Vivo Immunomodulatory Effects of Clozapine in Schizophrenia,' by M. Maes, E. Bosmans, G. Kenis, R. De Jong, R.S. Smith and H.Y. Meltzer published in the 1997 issue of 'Schizophrenic Research'.

  • Clozapine.  // Reactions Weekly;9/11/2010, Issue 1318, p17 

    The article describes the case of a 32-year-old man who developed persistent paroxysmal perceptual alterations while undergoing clozapine treatment for schizophrenia.

  • Prädeliktische Behandlungswege schizophrener Patienten der forensischen Psychiatrie. Piontek, K.; Kutscher, S.-U.; König, A.; Leygraf, N. // Der Nervenarzt;Jan2013, Vol. 84 Issue 1, p55 

    Background: The number of schizophrenic patients admitted to forensic hospitals according to section 63 of the German Criminal Code has increased continuously over the past years. Prior to admission to a forensic ward, two thirds of schizophrenic patients have been admitted to a general...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics